Catabasis Pharmaceuticals Inc. (CATB) announced Thursday morning that it has entered into a joint research collaboration with Sarepta Therapeutics (SRPT). The companies will explore a combination drug treatment approach for Duchenne muscular dystrophy.
from RTT - Before the Bell http://ift.tt/2dJRtjZ
via IFTTT
No comments:
Post a Comment